Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.

被引：0
|
作者：
Li, Jian
Xu, Ye
Zang, Aimin
Gao, Yunong
Gao, Quanli
Zhang, Yanqiao
Wang, Dong
Xu, Jianming
Yuan, Ying
Jiang, Haiping
Ying, Jieer
Shi, Chunmei
Deng, Yanhong
Wang, Jing
Liu, Tianshu
Huang, Yi
Xu, Yaling
Wang, Yidi
Fei, Cong
Shen, Lin
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Fudan Univ Shanghai, Canc Ctr, Shanghai, Peoples R China
[3] Hebei Univ, Affiliated Hosp, Hebei, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[5] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[6] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[8] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Zhejiang, Peoples R China
[9] Med Sch Zhejiang Univ, Affiliated Hosp 1, Zhejiang, Peoples R China
[10] Zhejiang Canc Hosp, Beijing, Peoples R China
[11] Fujian Med Univ, Union Hop, Fujian, Peoples R China
[12] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
[13] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[14] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[15] Hubei Canc Hosp, Wuhan, Hubei, Peoples R China
[16] BeiGene Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14556
引用
收藏
页数：1
相关论文
共 50 条
  • [31] FREQUENCY OF AND TESTING PATTERNS FOR MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS IN A US COMMUNITY ONCOLOGY SETTING
    Chase, M.
    Vasudevan, A.
    Amonkar, M.
    Myer, N.
    Wang, T.
    Prabhu, V
    Turzhitsky, V
    Spira, A.
    VALUE IN HEALTH, 2022, 25 (07) : S452 - S452
  • [32] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [33] Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana
    Mangan, Niamh
    Miller, Rowan E.
    Pikiel, Joanna
    Mirza, Mansoor R.
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer
    Tinker, Anna V.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 133 - 134
  • [34] Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201
    Ciombor, K. K.
    Hong, S.
    Eng, C.
    Yao, X.
    You, N.
    Das, P.
    Chakravarthy, A.
    O'Dwyer, P. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S104 - S104
  • [35] PATIENT-REPORTED OUTCOMES (PROS) IN THE GARNET TRIAL IN PATIENTS (PTS) WITH ADVANCED OR RECURRENT MISMATCH REPAIR DEFICIENT/MICROSATELITE INSTABILITY-HIGH (DMMR/MSI-H) ENDOMETRIAL CANCER (EC) TREATED WITH DOSTARLIMAB
    Kristeleit, Rebecca
    Mathews, Cara
    Redondo, Andres
    Huang, Joice
    Eliason, Laurie
    Im, Ellie
    Brown, Jubilee
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A40 - A41
  • [36] Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164
    Le, Dung T.
    Diaz Jr, Luis A.
    Kim, Tae Won
    Van Cutsem, Eric
    Geva, Ravit
    Jaeger, Dirk
    Hara, Hiroki
    Burge, Matthew
    O'Neil, Bert H.
    Kavan, Petr
    Yoshino, Takayuki
    Guimbaud, Rosine
    Taniguchi, Hiroya
    Elez, Elena
    Al-Batran, Salah-Eddin
    Boland, Patrick M.
    Cui, Yi
    Leconte, Pierre
    Marinello, Patricia
    Andre, Thierry
    EUROPEAN JOURNAL OF CANCER, 2023, 186 : 185 - 195
  • [37] Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
    Kristeleit, R.
    Matthews, C.
    Redondo, A.
    Huang, J.
    Eliason, L.
    Im, E.
    Brown, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S637 - S637
  • [38] A phase III study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW
    Abdullaev, Sandzhar
    Andre, Thierry
    Lei, Ming
    Lenz, Heinz-Josef
    Novotny, James
    Paulson, Andrew Scott
    Tejpar, Sabine
    Yamazaki, Kentaro
    Ledeine, Jean-Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [39] Clinical efficacy and biomarker analysis of pucotenlimab (HX008) in patients with previously treated advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A single-arm, multicenter, phase 2 study.
    Zhang, Bo
    Song, Yan
    Luo, Suxia
    Yin, Xianli
    Li, Enxiao
    Wang, Hui
    He, Yifu
    Liu, Zhihui
    Fan, Qingxia
    Liang, Xinjun
    Shu, Yongqian
    Liu, Yunpeng
    Xu, Nong
    Zhang, Shu
    Zhuang, Zhixiang
    Zhang, Jingdong
    Kou, Xiaoge
    Wang, Fen
    Zhu, Xiaodong
    Huang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 799 - 799
  • [40] Systematic literature review (SLR) of prognostic factors (PFs) in locally advanced rectal cancer (LARC) and mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer (RC).
    Capdevila, Jaume
    O'Donnell, Sean
    Borkowska, Katarzyna
    Frampton, James
    Betts, Marissa
    Maierhofer, Courtney
    Kalilani, Linda
    Garside, Jamie
    Wang, Huifen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 303 - 303
12345